Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide for treating diabetes

A technology for diabetes and glucagon, applied in specific peptides, hormone peptides, metabolic diseases, etc., to achieve the effects of easy industrial automation production, low production cost, and short synthesis cycle

Inactive Publication Date: 2015-03-11
马海龙
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the half-life of GLP-1 receptor agonists such as Liraglutide on the market has been extended, patients still need to inject the drug every day, and there is still room for improvement in the comfort of drug use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide for treating diabetes
  • Polypeptide for treating diabetes
  • Polypeptide for treating diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] SEQ ID NO: Solid-phase synthesis of polypeptides 1-12

[0043] The polypeptides of SEQ ID NO: 1-12 were synthesized using conventional methods of polypeptide synthesis in the art.

[0044] The glucagon-like peptide-1 (GLP-1) analogs synthesized according to the corresponding sequence were confirmed by electrospray mass spectrometry (ESI-MS) to confirm their respective molecular weights, which confirmed that the molecular weight was correct, indicating that the synthesis was successful.

Embodiment 2

[0045] Example 2 In vivo hypoglycemic activity of glucagon-like peptide-1 (GLP-1) analogs

[0046] Glucose and test compound were given at the same time: 11-week-old male Kunming mice were randomly assigned to 3 groups with 8 mice in each group. Only drink water and fast overnight. One group was intraperitoneally injected with 18mmol glucose solution (concentration 20%) and physiological saline per kilogram of mouse body weight; the other groups were intraperitoneally injected with 18mmol glucose solution and 20nmol GLP-1 compound solution (15μmol / L) per kilogram of mouse body weight. ). At 0, 15, 30, 45, 60 min, blood glucose level and blood glucose were measured with a blood glucose meter.

[0047] As shown in Table 1, since the modified glucagon-like peptide-1 (GLP-1) analog has anti-enzymatic and anti-renal filtration effects, and its biological half-life is greatly prolonged, the in vivo hypoglycemic experiments show that it promotes Insulin secretion is stronger than unmod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a long-lasting glucagon-like peptide-1 (GLP-1) analogue for treating diabetes. The GLP-1 analogue is obtained by modifying the natural GLP-1 and has longer duration of pharmacologic action; proved by experiments, the GLP-1 analogue can achieve a better diabetes treatment effect.

Description

Technical field [0001] The invention relates to glucagon-like peptide-1 (GLP-1) analogs and applications thereof. Background technique [0002] Diabetes is a group of metabolic diseases characterized by high blood sugar. Hyperglycemia is caused by defective insulin secretion or impaired biological effects, or both. The long-term high blood sugar in diabetes causes chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves. Diabetes is the third most serious chronic non-communicable disease threatening human health after tumors and cardiovascular diseases. Currently, there are about 300 million people with diabetes worldwide, and it is expected to increase to 500 million by 2025. In 2010, China had 92 million diabetic patients. China has become the second largest country with diabetes after India. Type 2 diabetes accounts for about 90% of the total number of diabetic patients. The most effective way to treat type 2 diabete...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/605A61K38/26A61P3/10
CPCC07K14/605A61K38/00
Inventor 马海龙
Owner 马海龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com